Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2026

Conditions
Silicosis
Interventions
DRUG

Silica 12CH

Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.

Trial Locations (1)

19138

HOHM Foundation, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HOHM Foundation

OTHER